Growth Differentiation Factor-15 is Associated with Cardiovascular Outcomes in Patients with Coronary Artery Disease

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2020 Aug 5

PMID 32746821

Citations 22

Authors

Man Li

Lei Duan

Yu-Lun Cai

Hui-Ying Li

Ben-Chuan Hao

Jian-Qiao Chen

Hong-Bin Liu

Affiliations

Soon will be listed here.

Abstract

Background: Growth differentiation factor-15 (GDF-15) is a marker of inflammation, oxidative stress and it is associated with adverse prognosis in cardiovascular disease. The aim of the present cohort study is to investigate the prognostic value of GDF-15 in patients with coronary artery disease (CAD) during long-term follow up.

Methods: A total of 3641 consecutive patients with CAD were prospectively enrolled into the study and followed up for major adverse cardiovascular events (MACEs) and all-cause death up to 5.3-7.6 years. Plasma GDF-15 was measured and clinical data and long-term events were registered. The patients were subsequently divided into three groups by the levels of GDF-15 and the prognostic value of GDF-15 level with MACEs and all-cause death was evaluated.

Results: After a median follow-up at 6.4 years later, 775 patients (event rate of 21%) had developed MACEs and 275 patients died (event rate of 7.55%). Kaplan-Meier analysis indicated that the patients with GDF-15 > 1800 ng/L were significantly associated with an increased risk of MACEs and all-cause death. Cox regression analysis indicated that GDF-15 > 1800 ng/L were independently associated with the composite of MACEs (HR 1.74; 95% CI 1.44-2.02; P < 0.001) and all-cause death (HR 2.04; 95% CI 1.57-2.61; P < 0.001). For MACEs, GDF-15 significantly improved the C-statistic (area under the curve, 0.583 [95% CI 0.559-0.606] to 0.628 [0.605-0.651]; P < 0.001), net reclassification index (0.578; P = 0.031), and integrated discrimination index (0.021; P = 0.027). For all-cause death, GDF-15 significantly improved the C-statistic (0.728 [95% CI 0.694-0.761] to 0.817 [0.781-0.846]; P < 0.001), net reclassification index (0.629; P = 0.001), and integrated discrimination index (0.035; P = 0.002).

Conclusions: In the setting of CAD, GDF-15 is associated with long-term MACEs and all-cause death, and provides incremental prognostic value beyond traditional risks factors.

Citing Articles

New Biomarkers in the Prognostic Assessment of Acute Heart Failure with Reduced Ejection Fraction: Beyond Natriuretic Peptides.

Cortes M, Lumpuy-Castillo J, Garcia-Talavera C, Arroyo Rivera M, de Miguel L, Bollas A Int J Mol Sci. 2025; 26(3).

PMID: 39940753 PMC: 11817831. DOI: 10.3390/ijms26030986.

Health implications of racial differences in serum growth differentiation factor levels among men with obesity.

Bathina S, Fuenmayor Lopez V, Prado M, Ballato E, Colleluori G, Tetlay M Physiol Rep. 2024; 12(23):e70124.

PMID: 39668628 PMC: 11638490. DOI: 10.14814/phy2.70124.

A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum.

Baldo M, Azevedo L, Coelho M, Martins E, Vilarinho L Diagnostics (Basel). 2024; 14(19).

PMID: 39410537 PMC: 11475613. DOI: 10.3390/diagnostics14192133.

Emerging Circulating Biomarkers for Enhanced Cardiovascular Risk Prediction.

Lee D J Lipid Atheroscler. 2024; 13(3):262-279.

PMID: 39355403 PMC: 11439747. DOI: 10.12997/jla.2024.13.3.262.

Prevalence and management of depressive symptoms in coronary heart disease patients and relationship with cardiovascular prognosis: a prospective cohort study.

Pan Y, Chen Y, Wu S, Ying P, Zhang Z, Tan X BMC Psychiatry. 2024; 24(1):644.

PMID: 39350149 PMC: 11443634. DOI: 10.1186/s12888-024-06117-z.

References

Wilson P, DAgostino R, Levy D, Belanger A, Silbershatz H, Kannel W . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47. DOI: 10.1161/01.cir.97.18.1837. View

Liu H, Lyu Y, Li D, Cui Y, Huang Y, Dai W . Potential relation between soluble growth differentiation factor-15 and testosterone deficiency in male patients with coronary artery disease. Cardiovasc Diabetol. 2019; 18(1):21. PMC: 6394066. DOI: 10.1186/s12933-019-0823-3. View

Schlittenhardt D, Schober A, Strelau J, Bonaterra G, Schmiedt W, Unsicker K . Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res. 2004; 318(2):325-33. DOI: 10.1007/s00441-004-0986-3. View

Buffon A, Biasucci L, Liuzzo G, dOnofrio G, Crea F, Maseri A . Widespread coronary inflammation in unstable angina. N Engl J Med. 2002; 347(1):5-12. DOI: 10.1056/NEJMoa012295. View

Jung S, Choi M, Ryu D, Yi H, Lee S, Chang J . Reduced oxidative capacity in macrophages results in systemic insulin resistance. Nat Commun. 2018; 9(1):1551. PMC: 5908799. DOI: 10.1038/s41467-018-03998-z. View

Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J . GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011; 17(5):581-8. DOI: 10.1038/nm.2354. View

Wollert K, Kempf T, Peter T, Olofsson S, James S, Johnston N . Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007; 115(8):962-71. DOI: 10.1161/CIRCULATIONAHA.106.650846. View

Kozakova M, Morizzo C, Goncalves I, Natali A, Nilsson J, Palombo C . Cardiovascular organ damage in type 2 diabetes mellitus: the role of lipids and inflammation. Cardiovasc Diabetol. 2019; 18(1):61. PMC: 6511166. DOI: 10.1186/s12933-019-0865-6. View

Bonaca M, Morrow D, Braunwald E, Cannon C, Jiang S, Breher S . Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2010; 31(1):203-10. DOI: 10.1161/ATVBAHA.110.213512. View

10.

Kempf T, Bjorklund E, Olofsson S, Lindahl B, Allhoff T, Peter T . Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007; 28(23):2858-65. DOI: 10.1093/eurheartj/ehm465. View

11.

Abulizi P, Loganathan N, Zhao D, Mele T, Zhang Y, Zwiep T . Growth Differentiation Factor-15 Deficiency Augments Inflammatory Response and Exacerbates Septic Heart and Renal Injury Induced by Lipopolysaccharide. Sci Rep. 2017; 7(1):1037. PMC: 5430818. DOI: 10.1038/s41598-017-00902-5. View

12.

Moore K, Tabas I . Macrophages in the pathogenesis of atherosclerosis. Cell. 2011; 145(3):341-55. PMC: 3111065. DOI: 10.1016/j.cell.2011.04.005. View

13.

Goff Jr D, Lloyd-Jones D, Bennett G, Coady S, DAgostino Sr R, Gibbons R . 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 63(25 Pt B):2935-2959. PMC: 4700825. DOI: 10.1016/j.jacc.2013.11.005. View

14.

Mensah G, Roth G, Fuster V . The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. J Am Coll Cardiol. 2019; 74(20):2529-2532. DOI: 10.1016/j.jacc.2019.10.009. View

15.

Lombardo A, Biasucci L, Lanza G, Coli S, Silvestri P, Cianflone D . Inflammation as a possible link between coronary and carotid plaque instability. Circulation. 2004; 109(25):3158-63. DOI: 10.1161/01.CIR.0000130786.28008.56. View

16.

Bauskin A, Brown D, Junankar S, Rasiah K, Eggleton S, Hunter M . The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res. 2005; 65(6):2330-6. DOI: 10.1158/0008-5472.CAN-04-3827. View

17.

Damman P, Kempf T, Windhausen F, van Straalen J, Guba-Quint A, Fischer J . Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Int J Cardiol. 2014; 172(2):356-63. DOI: 10.1016/j.ijcard.2014.01.025. View

18.

Khan S, Ng K, Dhillon O, Kelly D, Quinn P, Squire I . Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J. 2009; 30(9):1057-65. DOI: 10.1093/eurheartj/ehn600. View

19.

Lindholm D, James S, Gabrysch K, Storey R, Himmelmann A, Cannon C . Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. JAMA Cardiol. 2018; 3(12):1160-1166. PMC: 6583102. DOI: 10.1001/jamacardio.2018.3811. View

20.

Koopmann J, Buckhaults P, Brown D, Zahurak M, Sato N, Fukushima N . Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004; 10(7):2386-92. DOI: 10.1158/1078-0432.ccr-03-0165. View